- Home
- ENLV vs GDTC Comparison
ENLV vs GDTC Comparison
Compare ENLV & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- GDTC
- Stock Information
- Founded
- ENLV 2005
- GDTC 2018
- Country
- ENLV Israel
- GDTC Singapore
- Employees
- ENLV N/A
- GDTC N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- ENLV Health Care
- GDTC Health Care
- Exchange
- ENLV Nasdaq
- GDTC Nasdaq
- Market Cap
- ENLV 23.7M
- GDTC 21.5M
- IPO Year
- ENLV 1995
- GDTC 2023
- Fundamental
- Price
- ENLV $1.57
- GDTC $1.77
- Analyst Decision
- ENLV Strong Buy
- GDTC Buy
- Analyst Count
- ENLV 2
- GDTC 1
- Target Price
- ENLV $10.00
- GDTC $5.00
- AVG Volume (30 Days)
- ENLV 340.6K
- GDTC 17.4K
- Earning Date
- ENLV 08-29-2025
- GDTC 01-01-0001
- Dividend Yield
- ENLV N/A
- GDTC N/A
- EPS Growth
- ENLV N/A
- GDTC N/A
- EPS
- ENLV N/A
- GDTC N/A
- Revenue
- ENLV N/A
- GDTC $368,838.00
- Revenue This Year
- ENLV N/A
- GDTC $5.37
- Revenue Next Year
- ENLV N/A
- GDTC N/A
- P/E Ratio
- ENLV N/A
- GDTC N/A
- Revenue Growth
- ENLV N/A
- GDTC N/A
- 52 Week Low
- ENLV $0.81
- GDTC $1.20
- 52 Week High
- ENLV $1.76
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- ENLV 68.20
- GDTC 34.10
- Support Level
- ENLV $1.31
- GDTC $1.79
- Resistance Level
- ENLV $1.66
- GDTC $1.88
- Average True Range (ATR)
- ENLV 0.13
- GDTC 0.06
- MACD
- ENLV 0.01
- GDTC -0.00
- Stochastic Oscillator
- ENLV 83.33
- GDTC 4.88
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.